Abstract
Purpose: Emerging biomarkers from medical imaging or molecular characterization of tumor biopsies open up for combining the two and exploiting their synergy in treatment planning. We compared pretreatment classification of locally advanced cervical cancer patients by two previously validated imaging- and gene-based hypoxia biomarkers, appraised the influence of intratumor heterogeneity, and investigated the benefit of combining them in prediction of chemoradiotherapy failure. Experimental Design: Hypoxic fraction, determined from dynamic contrast enhanced (DCE)-MR images, and an expression signature of 6 hypoxia-responsive genes were used as imaging- and gene-based biomarker, respectively, in 118 patients. Intratumor heterogeneity was assessed by variance analysis. The biomarkers were combined using a dimension reduction procedure. Results: The two biomarkers classified 75% of the patients with the same hypoxia status. Inconsistent classification in some cases was not related to imaging-defined intratumor heterogeneity in hypoxia, and hypoxia status of the slice covering the biopsy region was representative of the whole tumor. Hypoxia assessed by gene expression was independent on tumor cell fraction in the biopsies and showed minor heterogeneity across multiple samples in 9 tumors. Inconsistent classification was therefore rather caused by a difference in the hypoxia phenotype reflected by the biomarkers, providing a rational for combining them into a composite score. This score showed improved prediction of treatment failure (HR:7.3) compared to imaging (HR:3.8) and genes (HR:3.0) and significant prognostic impact in multivariate analysis with clinical variables. Conclusion: Combining our imaging- and gene-based biomarkers enables more precise and informative assessment of hypoxia-related chemoradiotherapy resistance in cervical cancer.
Competing Interest Statement
HL is registered as inventor of a patent application covering the clinical use of the hypoxia gene signature (WO2013/124738).
Funding Statement
The work was supported by grants from The Norwegian Cancer Society (Grant No 107438 and 182451), The South-Eastern Norway Regional Health Authority (Grant No 2015020), and The Norwegian Research Council (ELIXIR Norway).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Committee for Medical and Health Research Ethics in southern Norway (S-01129). All patients gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data have been deposited in the gene expression omnibus (GEO) database (GSE146114), which will be released upon publication.
